NCT02255565View on ClinicalTrials.gov

Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study

PHASE4CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

October 31, 2016

Conditions
ADHDAutism
Interventions
DRUG

Very Low Dose Quillivant XR

Oral suspension dose once a day increasing to a 10mg dose

DRUG

Low Dose Quillivant XR

Oral suspension dose once a day increasing to a 20mg dose

DRUG

Moderate Dose Quillivant XR

Oral suspension dose once a day increasing to a 40mg dose

Trial Locations (1)

98105

Seattle Children's Hospital, Seattle

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Seattle Children's Hospital

OTHER

NCT02255565 - Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study | Biotech Hunter | Biotech Hunter